Fig. 6.
Effects of twice daily treatments on growth and survival of CML cells derived from (A, B) patient 2, (C, D) patient 3 (E, F) healthy control individual of SpA4-anti-bcr (•), SpA4-(M5)anti-bcr (▪), SpA2-anti-bcr (▴), SpA4-anti-b3a2 (□), SpA4-anti-b2a2 (○), anti-b3a2 (▵), SpA4-(M6)anti-b3a2 (◊) or anti-bcr (⧫). ODNs were added twice daily at a concentration of 5 μmol/L. Data points are the ratio of the viable cell numbers for the treated and untreated cultures × 100. Experiments were performed in duplicate and results averaged.